Edition:
United Kingdom

Idorsia Ltd (IDIA.S)

IDIA.S on Swiss Exchange

24.08CHF
2:59pm BST
Change (% chg)

CHF0.18 (+0.75%)
Prev Close
CHF23.90
Open
CHF23.82
Day's High
CHF24.28
Day's Low
CHF23.50
Volume
270,499
Avg. Vol
324,331
52-wk High
CHF25.02
52-wk Low
CHF15.20

Latest Key Developments (Source: Significant Developments)

Idorsia FY US GAAP Loss Of CHF 8 Million
Tuesday, 6 Feb 2018 

Feb 6 (Reuters) - Idorsia Ltd ::US GAAP OPERATING RESULTS 2017: YTD LOSS OF CHF 8 MILLION; Q4 PROFIT OF CHF 71 MILLION.NON-GAAP OPERATING INCOME 2017: YTD CHF 8 MILLION; Q4 CHF 79MILLION.GUIDANCE FOR 2018: NON-GAAP OPERATING EXPENSES AROUND CHF 390 MILLION.FY US GAAP REVENUES OF CHF 158 MILLION.  Full Article

Idorsia Forms Research Collaboration With Roche In Field Of Cancer Immunotherapy
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - IDORSIA LTD ::IDORSIA FORMS RESEARCH COLLABORATION WITH ROCHE IN THE FIELD OF CANCER IMMUNOTHERAPY.PARTIES WILL COLLABORATE ON DISCOVERY OF PRODUCTS THROUGH FORMATION OF A JOINT COMMITTEE, CHAIRED BY IDORSIA.ROCHE WILL PAY IDORSIA AN UPFRONT PAYMENT OF CHF 15 MILLION.ROCHE CAN THEN EXCLUSIVELY LICENSE IDORSIA COMPOUNDS AND COMPOUNDS RESULTING FROM COLLABORATION, FOR FURTHER PAYMENT OF 35 MILLION.IDORSIA WILL BE ELIGIBLE TO RECEIVE ONE-TIME DEVELOPMENT AND REGULATORY MILESTONES OF UP TO CHF 410 MILLION.IDORSIA ALSO BE ENTITLED TO ONE-TIME MILESTONES BASED ON SALES THRESHOLDS, AND TIERED ROYALTIES ON ANNUAL NET SALES.  Full Article

Idorsia ‍Q3 US GAAP operating loss at CHF 68 mln
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - IDORSIA LTD :‍US GAAP OPERATING LOSS IN Q3 2017: CHF 68 MILLION / YTD* 2017: CHF 79 MILLION​.‍NON-GAAP** OPERATING LOSS IN Q3 2017: CHF 61 MILLION / YTD* 2017: CHF 71 MILLION​.‍GUIDANCE FOR FULL YEAR 2017: NON-GAAP OPERATING EXPENSES OF CHF 160-170 MILLION​.‍AT END OF Q3, IDORSIA'S LIQUIDITY AMOUNTED TO CHF 952 MILLION​.‍9MTH US GAAP NET LOSS AMOUNTED TO CHF 82 MILLION RESULTING IN A NET LOSS PER SHARE OF CHF 0.73​.  Full Article

BRIEF-Idorsia Says Janssen Reports Positive Top-Line Phase 3 Results For Ponesimod

* JANSSEN REPORTS POSITIVE TOP-LINE PHASE 3 RESULTS FOR PONESIMOD IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS